The U.S. Food and Drug Administration has downgraded the classification of full-field digital mammography devices from high risk to medium risk, making it easier for companies to bring the technology to market, the agency announced today.
FDA eases rules on digital mammography devices
Nov 3, 2010
Latest in Breast
DBT performance improves with patient age
October 23, 2026
FDA clears SimBioSys's breast cancer risk software
October 16, 2026
Half of false-negative DBT exams are missed cancers
October 5, 2026
















